Overview
Overview
Parent Cell: Akira Dopamine-Secreting Neurocytes differentiated from UCT-WJ-MSCs | Dopamine-regulatory growth factors and miRNAs for dopamine-secreting neurocytes repair and regeneration
| Stats | Details |
|---|---|
| Particle Count | ≥ 1.1 × 10¹¹ exosomes per vial (NTA-validated) |
| Exosome Size | 30–150 nm mean diameter |
| Growth Factors | GDNF, BDNF, TGF-β3, Nurr1-associated factors, FGF-8, SHH, Wnt1 |
| miRNA Cargo | miR-132, miR-134, miR-9, miR-7, miR-153 |
| Identity Markers | TH (tyrosine hydroxylase)+, DAT+, Nurr1+, FOXA2+ |
| Format | Sterile aqueous suspension in PBS; ready-to-use upon thaw |
| Storage | −20 °C; do not refreeze |
| Regulatory Status | For Educational Purposes Only |
Definition
What Are Exosomes?
Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.
The Akira Dopamine Exosome Matrix is derived from dopamine-secreting neurocytes produced through a multi-stage directed differentiation protocol that recapitulates midbrain dopaminergic neuron development. This protocol employs sequential exposure to SHH, FGF-8, and Wnt1 to specify ventral mesencephalic identity, followed by Nurr1 and FOXA2 induction to produce a cell population expressing the key transcription factors and surface markers of substantia nigra pars compacta (SNpc) dopaminergic neurons.
The exosomes harvested from these dopaminergic neurocytes carry a specialized cargo profile reflecting their lineage — GDNF-associated signaling molecules, Nurr1-regulated transcription factor cargo, and miRNAs specifically associated with dopaminergic neuron identity and survival (miR-7, miR-132, miR-153). This preparation provides targeted neuroprotective and neuroregenerative signaling for the dopaminergic circuits of the nigrostriatal pathway.
Unlike general neural exosome preparations, the Dopamine Exosome Matrix is specifically enriched for the molecular signals relevant to dopaminergic neuron survival, dopamine synthesis, and synaptic transmission — making it uniquely applicable to the educational and research contexts of Parkinson's disease, dopamine system dysregulation, and related movement disorders.[1]
Process
Mechanism of Action
Dopaminergic Neuron Survival & GDNF Signaling: GDNF is the most potent known survival factor for dopaminergic neurons, signaling through the RET receptor tyrosine kinase to activate PI3K/Akt and MAPK/ERK pathways. Dopamine exosome cargo delivers GDNF-associated molecular signals that mimic and amplify endogenous GDNF signaling within the nigrostriatal circuit. This provides trophic support for surviving dopaminergic neurons and may slow progressive degeneration in Parkinson's-relevant research models.[2]
Nurr1-Mediated Dopaminergic Identity Maintenance: Nurr1 (NR4A2) is the master transcription factor for dopaminergic neuron identity, regulating TH (tyrosine hydroxylase), DAT (dopamine transporter), and VMAT2 expression. miRNA cargo from dopaminergic neurocyte exosomes promotes Nurr1 target gene expression in recipient neurons, supporting maintenance of the dopaminergic phenotype and dopamine synthesis capacity.
Neuroinflammation Suppression in the Substantia Nigra: Dopaminergic neurons are particularly vulnerable to neuroinflammation-driven degeneration. miR-7 suppresses NLRP3 inflammasome activation in microglia, reducing IL-1β and IL-18 in the substantia nigra microenvironment. miR-153 inhibits α-synuclein (SNCA) expression, addressing a key pathological driver of Parkinson's disease. This dual anti-inflammatory and anti-aggregation mechanism is unique to the dopaminergic exosome lineage.[3]
Synaptic Dopamine Signaling Restoration: TGF-β3 and BDNF in the secretome support synaptic remodeling and dendritic spine maintenance in striatal neurons that receive dopaminergic input from the substantia nigra. This supports restoration of functional synaptic transmission in the nigrostriatal pathway, relevant to motor function and reward circuitry in research contexts.
α-Synuclein Pathology Modulation: miR-153 directly targets the SNCA (α-synuclein) 3'UTR, reducing α-synuclein protein levels in recipient neurons. Excess α-synuclein aggregation is the defining pathological hallmark of Parkinson's disease and multiple system atrophy. Exosome-mediated delivery of miR-153 represents a potential mechanism for modulating α-synuclein burden in preclinical research models.
Biomarkers
Key Molecular Cargo
| Molecule / miRNA | Therapeutic Function |
|---|---|
| GDNF | Glial cell line-derived neurotrophic factor; most potent dopaminergic neuron survival factor; RET/PI3K/Akt signaling |
| BDNF | Dopaminergic neuron survival co-factor; synaptic plasticity in striatal circuits; TrkB pathway activation |
| TGF-β3 | Synaptic remodeling; anti-fibrotic; striatal plasticity support |
| Nurr1 cargo | Dopaminergic identity transcription factor; regulates TH, DAT, VMAT2 expression |
| FGF-8 | Midbrain dopaminergic specification factor; retained in exosome cargo |
| miR-7 | NLRP3 inflammasome inhibition; microglial activation suppression; neuroprotective in SN microenvironment |
| miR-132 | Synaptic plasticity; CREB signaling; dendritic spine density in striatal neurons |
| miR-153 | α-Synuclein (SNCA) suppression; anti-aggregation mechanism; Parkinson's-relevant miRNA |
| TH (marker) | Tyrosine hydroxylase — rate-limiting enzyme in dopamine synthesis; lineage identity marker |
| DAT (marker) | Dopamine transporter — synaptic dopamine reuptake; lineage identity marker |
Applications
Therapeutic Applications
???
Evidence
Clinical & Preclinical Evidence
???